Navigation Links
Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
Date:8/25/2010

WALTHAM, Mass., Aug. 25  /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's Depakote/Abbott's Depakote ER, generics), combined with projected generic erosion of the atypical antipsychotic drug class will cause a precipitous $2.3 billion decline in the bipolar disorder drug market over the next decade.

The Pharmacor 2010 findings from the topic entitled Bipolar Disorder reveal that although patient share for atypical antipsychotics will increase through 2019, particularly in France, Germany, Italy, Spain, the United Kingdom and Japan, sales of atypical antipsychotics will decline significantly over the forecast period owing to the generic erosion of key agents such as AstraZeneca/Astellas's Seroquel/AstraZeneca's Seroquel XR, Eli Lilly's Zyprexa, Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and Pfizer's Geodon.

The Pharmacor 2010 findings reveal that bipolar depression is the largest unmet need in bipolar disorder, as experts consistently indicate that few therapies achieve sufficient efficacy in this market segment. Two emerging atypical antipsychotics will likely gain approval for bipolar depression: Forest Laboratories/Gedeon Richter/Mitsubishi Pharma's cariprazine and Dainippon Sumitomo Pharma/Sepracor's (soon to be Sunovion Pharmaceuticals) lurasidone. Lurasidone, which is expected to gain approval for bipolar depression in 2012, will become a market leader in 2019.

"The bipolar depression market segment represents the greatest commercial opportunity and we expect that lurasidone will gain approval for bipolar depression in 2012, following its launch in 2011 for the treatment of schizophrenia," said Decision Resources Analyst Alana Simorellis, Ph.D. "Dainippon Sumitomo Pharma and S
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Biodel to Raise $9.4 Million Through Registered Direct Offering
2. Managed Care Pull-Through Initiatives Suffer from Poor Measurement of ROI
3. Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ)
4. Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
5. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
6. Arizona Residents Get Help With Medicines Through PPA 2.0
7. Gaining Visibility and Control Over Purchases of Medical Devices is the Focus of a GHX Presentation at Premier Annual Breakthroughs Conference and Exhibition
8. NanoPowers Raises CHF 5 Million ($4.5 Million) in Series A Financing to Support Development of Breakthrough Urinary Incontinence Device
9. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
10. RunE2E and Freudenberg IT Create Customer Value Through Implementation of SAP® CRM in Hosted, Private Cloud
11. Hothead Technologies Partners with Shafer Enterprises to Provide Break-Through Technology to Monitor and Manage Normothermia in Medical Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, Inc. ... devices to address infectious disease, cancer and other ... Research Projects Agency (DARPA) has informed the Company ... proceed with year four of a five-year $5.9 ... September 30, 2011 under DARPA,s Dialysis-Like Therapeutics (DLT) ...
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... quarter and fiscal 2014 ended July 31, 2014 on Monday, ... call to discuss the results at 11:00 AM ET. Participating ... Chairman; Andrew A. Krakauer , President and CEO; ... Craig A. Sheldon , Senior Vice President, CFO and Treasurer; ...
(Date:9/22/2014)... SAN FRANCISCO , Sept. 22, 2014  Sutro ... FierceBiotech as one of 2014,s Fierce 15 ... promising private biotechnology companies in the industry.  ... A-list group of backers as well as industry partners ... developing antibody-drug conjugates and bispecifics," says John Carroll ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... March 22 Cambrex Corporation (NYSE: ... a privately held company that is a leader in ... Wiesbaden, Germany and offers cost effective customized ... pharmaceutical industry, with the ability to utilize its tool ...
... Inc. (OTC Bulletin Board: GOVX), a biotechnology company that is developing and testing innovative HIV/AIDS vaccines, has engaged The Investor Relations Group ("IRG"), ... , ... , ... ...
Cached Medicine Technology:Cambrex Acquires IEP GmbH 2Cambrex Acquires IEP GmbH 3GeoVax Labs Engages The Investor Relations Group 2GeoVax Labs Engages The Investor Relations Group 3GeoVax Labs Engages The Investor Relations Group 4
(Date:9/22/2014)... Alan Mozes HealthDay Reporter ... take note: Many American parents are aware of online physician-rating ... a pediatrician for their children, according to a new national ... than 1,600 parents -- further suggest that negative online ratings ... doctor has been recommended by a neighbor. Conversely, a ...
(Date:9/22/2014)... Asians living in Canada have a higher rate of ... with while people, McMaster researchers have found. , ... Medical Association Journal (CMAJ Open) and may be ... fastest-growing ethnic groups in the country is the more ... comprising about three percent of the population. They include ...
(Date:9/22/2014)... Kessler researchers have published a pilot study showing ... in people with multiple sclerosis (MS). Improvements ... stress, and pain. "Development and effectiveness of ... MS: Description and outcomes" was epublished ahead of ... Journal of MS Care (doi: 10.7224/1537-2073.2013-045). The ...
(Date:9/22/2014)... new prescription devices approved by the U.S. Food and ... with migraine headaches who don,t tolerate migraine medications well, ... the Cefaly -- is designed to prevent migraines, while ... to be used when migraines first start, according to ... for alternative migraine treatments. Because these devices aren,t ingested ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Severe weather can occur ... time. That’s why, as part of National Preparedness Month, Amica ... your family prepare for the unexpected:, , Build ... as nonperishable food and one gallon of water per person per ... Create an evacuation plan that includes pets so your family knows ...
Breaking Medicine News(10 mins):Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2
... N.J., Feb. 17 Novo Nordisk, a global healthcare ... of Andy Ajello as vice president for National Diabetes ... Executive Team and will report directly to Jerzy Gruhn, ... recently the associate vice president of Diabetes Sales for ...
... Little known language in the economic stimulus ... efforts by nonprofit hospitals - resulting in fewer ... of essential health care services provided to the ... the 11th hour thanks to the efforts of ...
... CryoLife, Inc. (NYSE: CRY ), a,biomaterials, medical ... Food and Drug Administration (FDA) has cleared a new ... The new labeling claim,relates to reducing a component of ... CryoValve SG pulmonary human heart ...
... Year,s Most Common ClaimsBREA, Calif., Feb. 17 Not ... and cuddly. Take ear infections, for example, or skin ... (VPI), the nation,s oldest and largest provider of pet ... to find the year,s most common pet maladies. The ...
... "natural" ingredients should be regarded as a driver for ... 17 According to Kline & Company,s study ... 2008: U.S. and Europe , botanicals consumption is growing ... average growth of 5.4%. The increased use of botanicals ...
... DIEGO, Feb. 17 Tracon Pharmaceuticals, a biotechnology company ... announced today that its three clinical stage cancer therapeutics ... 100th Annual Meeting of the American Association for Cancer ... program targets a unique pathway with the potential for ...
Cached Medicine News:Health News:Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts 2Health News:Philanthropic Fundraising Activities in Stimulus Bill Preserved Thanks to the Efforts of the Association for Healthcare Philanthropy 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 3Health News:Sick as a Dog: Pets' Top Medical Conditions of 2008 2Health News:Sick as a Dog: Pets' Top Medical Conditions of 2008 3Health News:Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care 2Health News:Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care 3Health News:Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009 2Health News:Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: